Poison prevention packaging requirements; exemption of hormone replacement therapy products. Final rule.
The Commission is amending its child-resistant packaging requirements to exempt hormone replacement therapy ("HRT") products containing one or more progestogen or estrogen substances. Current exemptions cover some HRT products, but not others. This rule would uniformly exempt from child resistant packaging requirements all HRT products that rely solely on the activity of one or more progestogen or estrogen substances.
D002648:Child; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence*; D004349:Drug Packaging / Q000331:legislation & jurisprudence*; D004967:Estrogens / Q000145:classification* / Q000633:toxicity; D005260:Female; D020249:Hormone Replacement Therapy / Q000145:classification*; D006801:Humans; D007880:Legislation, Drug / Q000145:classification; D011041:Poisoning / Q000517:prevention & control*; D011372:Progestins / Q000145:classification* / Q000633:toxicity; D014481:United States
D004967:Estrogens; D011372:Progestins